(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...

U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug, the company said Friday in its ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...

The WisdomTree U.S. High Dividend Fund (NYSEARCA:DHS) offers retirees monthly income and capital appreciation. With $1.3 billion in assets and a 3.46% yield, this ETF holds diversified high-dividend U ...

Medicare Part D coverage is never static, but 2026 is shaping up to be a particularly volatile year for formularies. Thanks to new legislation and aggressive cost-cutting by plan administrators, ...

No more waiting: Humira’s judgment day has finally arrived. The first Humira biosimilar, Amgen’s Amjevita, is set to reach the market Tuesday and kick off a tsunami-sized wave of competition. With ...

Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

AbbVie owns two of the best-selling drugs in the world in Humira and Imbruvica. But to build and defend its market monopoly for the two heavyweights, the company has repeatedly raised prices and ...

You might call it the Swiss army knife of pharmaceutical drugs. Since it hit the market in 2002 to treat rheumatoid arthritis, Humira has racked up one governmental approval after another to treat ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...